Prognostic biomarkers in diffuse large B-cell lymphoma.
暂无分享,去创建一个
[1] G Flandrin,et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] H. Koga,et al. Prognostic significance of the F‐box protein Skp2 expression in diffuse large B‐cell lymphoma , 2003, American journal of hematology.
[3] A. Gearing,et al. Design and therapeutic application of matrix metalloproteinase inhibitors. , 1999, Chemical reviews.
[4] M Tubiana,et al. Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.
[5] G Flandrin,et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] William Arbuthnot Sir Lane,et al. Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.
[7] P. Marynen,et al. FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations , 2005, Leukemia.
[8] S. Fox,et al. Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. , 1994, Cancer research.
[9] K. Offit,et al. BCL-6 protein is expressed in germinal-center B cells. , 1995, Blood.
[10] Tetsuo Himi,et al. Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non‐Hodgkin lymphoma , 2004, Cancer.
[11] H. Joensuu,et al. Elevated serum endostatin is associated with poor outcome in patients with non‐Hodgkin lymphoma , 2003, Cancer.
[12] R. Friesel,et al. Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[13] Katia Basso,et al. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. , 2003, Blood.
[14] T M Grogan,et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[15] L. Staudt,et al. Transcriptional repression by the proto-oncogene BCL-6. , 1996, Oncogene.
[16] Emili Montserrat,et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. , 2003, Blood.
[17] C. Mackay,et al. Expression and modulation of CD44 variant isoforms in humans , 1994, The Journal of cell biology.
[18] G. Pinkus,et al. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. , 1986, Annals of internal medicine.
[19] H. Dvorak,et al. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. , 1999, Current topics in microbiology and immunology.
[20] A. Levine. p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.
[21] J. Blay,et al. Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. , 1993, Blood.
[22] Harold E. Dvorak,et al. Angiogenesis: a Dynamic Balance of Stimulators and Inhibitors , 1997, Thrombosis and Haemostasis.
[23] D. Rifkin,et al. Biological roles of fibroblast growth factor-2. , 1997, Endocrine reviews.
[24] F. Mitelman,et al. Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study. , 2002, International journal of oncology.
[25] C. Meijer,et al. Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas , 2004, Leukemia.
[26] B. Nathwani,et al. A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project , 1997 .
[27] S. Jagannath,et al. Risk classification as the basis for clinical staging of diffuse large-cell lymphoma derived from 10-year survival data. , 1989, Blood.
[28] H. Joensuu,et al. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. , 1997, Blood.
[29] T. Molina,et al. CD10 expression in diffuse large B-cell lymphomas does not influence survival , 2004, Virchows Archiv.
[30] S. Barrans,et al. Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. , 2004, Blood.
[31] S. Jalkanen,et al. Serum CD44 in malignant lymphoma: an association with treatment response. , 1994, Blood.
[32] T. Grogan,et al. Tumor-infiltrating T-lymphocytes in B-cell diffuse large cell lymphoma related to disease course. , 1990, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[33] J Diebold,et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. , 2000, Blood.
[34] R. Tibshirani,et al. Molecular analysis of immunoglobulin genes in diffuse large B-cell lymphomas. , 2000, Blood.
[35] M. Radmacher,et al. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. , 2003, Journal of the National Cancer Institute.
[36] Ash A. Alizadeh,et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. , 2004, The New England journal of medicine.
[37] H. Müller-Hermelink,et al. Genetic analysis of de novo CD5+ diffuse large B-cell lymphomas suggests an origin from a somatically mutated CD5+ progenitor B cell. , 2003, Blood.
[38] M. Piris,et al. © 1999 Cancer Research Campaign Article no. bjoc.1999.0539 p27 KIP1 is abnormally expressed in Diffuse Large B-Cell , 2022 .
[39] G. Salles,et al. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. , 2004, Blood.
[40] J. Bell,et al. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[41] R. Gascoyne,et al. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[42] Robert Tibshirani,et al. HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma. , 2003, Blood.
[43] S. Korsmeyer,et al. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around Jh on chromosome 14 and near a transcriptional unit on 18 , 1985, Cell.
[44] H. Dvorak,et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.
[45] K. Karube,et al. Prognostic significance of hepatocyte growth factor and c‐MET expression in patients with diffuse large B‐cell lymphoma , 2004, British journal of haematology.
[46] S. Tucker,et al. International prognostic index‐based outcomes for diffuse large B‐cell lymphomas , 2002, Cancer.
[47] R. Tibshirani,et al. Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[48] Geoffrey J McLachlan,et al. Selection bias in gene extraction on the basis of microarray gene-expression data , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[49] S. Barrans,et al. Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B‐cell lymphoma , 2002, British journal of haematology.
[50] P. Pandolfi,et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation , 1997, Nature Genetics.
[51] L. Staudt,et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.
[52] Ash A. Alizadeh,et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. , 2002, Blood.
[53] D. Fearon,et al. Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. , 2000, Annual review of immunology.
[54] S. Jalkanen,et al. Elevated serum CD44 level is associated with unfavorable outcome in non-Hodgkin's lymphoma. , 1997, Blood.
[55] T. Grogan,et al. Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. , 1988, Blood.
[56] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[57] D. Altieri,et al. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma , 1997, Nature Medicine.
[58] J Hermans,et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. , 1998, Blood.
[59] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[60] Y. Honma,et al. Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma. , 2001, Blood.
[61] R. Schreiber,et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death , 1990, Nature.
[62] K. Franssila,et al. BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. , 1997, Blood.
[63] T. Golub,et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. , 2003, Blood.
[64] L. Pasqualucci,et al. Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia. , 2000, Blood.
[65] R Tibshirani,et al. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. , 2001, Blood.
[66] Prognostic models for diffuse large b‐cell lymphoma , 2000, Hematological oncology.
[67] J Hermans,et al. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] C. Sherr. Cancer Cell Cycles , 1996, Science.
[69] Yasodha Natkunam,et al. Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation. , 2004, Blood.
[70] K. Ohshima,et al. Prognostic clinicopathologic factors, including immunologic expression in diffuse large B‐cell lymphomas , 1999, Pathology international.
[71] I. Marugán,et al. Soluble intercellular adhesion molecule-1 (s-ICAM-1/s-CD54) in diffuse large B-cell lymphoma: association with clinical characteristics and outcome. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[72] P. Herrlich,et al. Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44 , 1993, The Journal of experimental medicine.
[73] A. López-Guillermo,et al. Expression of the adhesion molecule ICAM-1 in non-Hodgkin's lymphoma: relationship with tumor dissemination and prognostic importance. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[74] P. Mclaughlin,et al. A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the 'tumor score'. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.
[75] Z. Werb,et al. How matrix metalloproteinases regulate cell behavior. , 2001, Annual review of cell and developmental biology.
[76] C. Gundy,et al. Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. , 2005, Blood.
[77] S. Kvaløy,et al. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma—a Nordic Lymphoma Group study , 2004, Annals of Hematology.
[78] Ash A. Alizadeh,et al. The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. , 1999, Cold Spring Harbor symposia on quantitative biology.
[79] P. Gaulard,et al. p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[80] L. Staudt,et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. , 2004, Blood.
[81] W. Chan,et al. Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma , 2005, Modern Pathology.
[82] Rosenberg Sa. Validity of the Ann Arbor staging classification for the non-Hodgkin's lymphomas. , 1977 .
[83] R S Chaganti,et al. BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[84] K. Ohshima,et al. CD10 and Bcl10 expression in diffuse large B‐cell lymphoma: CD10 is a marker of improved prognosis , 2001, Histopathology.
[85] H. Nakamine,et al. Clinical Significance of Intracytoplasmic nm23-H1 Expression in Diffuse Large B-Cell Lymphoma , 2004, Clinical Cancer Research.
[86] T. Lebien,et al. The common acute lymphoblastic leukemia antigen (CD10)--emancipation from a functional enigma. , 1989, Blood.
[87] J Diebold,et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). , 1996, Blood.
[88] H. Shiku,et al. De novo CD5+ diffuse large B-cell lymphomas express VH genes with somatic mutation. , 1998, Blood.
[89] M. Teitell,et al. PKC-β controls IκB kinase lipid raft recruitment and activation in response to BCR signaling , 2002, Nature Immunology.
[90] Ellen,et al. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. , 1994, Blood.
[91] N. Ferrara,et al. The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.
[92] H Stein,et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.
[93] J. Cheville,et al. p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. , 1999, The American journal of pathology.
[94] S. Tucker,et al. A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[95] S. Rosenberg. Validity of the Ann Arbor staging classification for the non-Hodgkin's lymphomas. , 1977, Cancer treatment reports.
[96] J C Reed,et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. , 1997, Blood.
[97] Takashi Akasaka,et al. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. , 2002, Blood.
[98] S. le Cessie,et al. Lack of Prognostic Significance of BCL2 and p53 Protein Overexpression in Elderly Patients with Diffuse Large B-cell Non-Hodgkin's Lymphoma: Results from a Population-based Non-Hodgkin's Lymphoma Registry , 2004, Leukemia & lymphoma.
[99] H. Joensuu,et al. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. , 2000, Blood.
[100] G. Fountzilas,et al. Diffuse Large Cell Lymphomas: Identification of Prognostic Factors and Validation of the International Non-Hodgkin’s Lymphoma Prognostic Index , 1998, Oncology.
[101] U. Jaeger,et al. Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[102] S. Sohn,et al. Prognostic significance of bcl‐2, bax, and p53 expression in diffuse large B‐cell lymphoma , 2003, American journal of hematology.
[103] J. Cigudosa,et al. Chromosomal and gene amplification in diffuse large B-cell lymphoma. , 1998, Blood.
[104] P. Johnson,et al. The prognostic significance of serum levels of soluble intercellular adhesion molecules‐1 in patients with primary extranodal non‐Hodgkin lymphomas , 2000, Cancer.
[105] S. Jagannath,et al. Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[106] T. Grogan,et al. HLA-DR (Ia) immune phenotype predicts outcome for patients with diffuse large cell lymphoma. , 1988, The Journal of clinical investigation.
[107] R. Coffman,et al. Interleukin-10 and the interleukin-10 receptor. , 2001, Annual review of immunology.
[108] F. Mandelli,et al. Pathogenetic and clinical implications of Bcl‐6 and Bcl‐2 gene configuration in nodal diffuse large B‐cell lymphomas , 1997, The Journal of pathology.
[109] S. Poppema,et al. Human marginal zone b cells are not an activated b cell subset: strong expression of cd21 as a putative mediator for rapid b cell activation , 1989, European journal of immunology.
[110] M. Teitell,et al. PKC-beta controls I kappa B kinase lipid raft recruitment and activation in response to BCR signaling. , 2002, Nature immunology.
[111] Motohiro Ito,et al. CD21S antigen expression in tumour cells of diffuse large B‐cell lymphomas is an independent prognostic factor indicating better overall survival , 2004, British journal of haematology.
[112] A. Naganuma,et al. Negative autoregulation of BCL-6 is bypassed by genetic alterations in diffuse large B cell lymphomas , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[113] Adrian Wiestner,et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[114] Ramón Bosch,et al. Building an outcome predictor model for diffuse large B-cell lymphoma. , 2004, The American journal of pathology.
[115] G. Pinkus,et al. The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[116] D. Hanahan,et al. Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.
[117] D C Linch,et al. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. , 1996, Blood.
[118] T. Grogan,et al. Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[119] M. Hollstein,et al. p53 and human cancer: the first ten thousand mutations. , 2000, Advances in cancer research.
[120] Atul Butte,et al. The use and analysis of microarray data , 2002, Nature Reviews Drug Discovery.
[121] Meland,et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[122] H. Tilly,et al. LAZ3, a novel zinc–finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas , 1993, Nature Genetics.
[123] H. Saito,et al. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. , 1997, The New England journal of medicine.
[124] S. Pals,et al. Cell adhesion receptors in lymphoma dissemination. , 2000, Blood.
[126] P. Gaulard,et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). , 2003, Blood.
[127] M. Ladanyi,et al. Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. , 1994, The New England journal of medicine.
[128] M. Piccinni,et al. T lymphocytes from invaded lymph nodes in patients with B-cell-derived non-Hodgkin's lymphoma: reactivity toward the malignant clone. , 1990, Blood.
[129] J. Banchereau,et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[130] J. Sklar,et al. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[131] J. Armitage,et al. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[132] Todd,et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.